Cancer Immunotherapy Market To Surpass USD 24 Billion by 2020

There are several advantages which are offered by immunotherapy in the treatment of some types of
cancers as compared to traditional chemotherapies and molecularly targeted agents.
Cancer immunotherapy, in recent years has become one of the most sought after treatment options for
cancer. The major reason for this rising popularity is the dependence of this method on biological molecules
which occur naturally and are used to enhance the immune system. This factor has made cancer
immunotherapy the most natural and patient friendly when compared to all the scientifically validated
methods for treating cancer. In some cases, immunotherapy is alone used to treat cancer, while in some
other cases it is used in combination with traditional treatments in order to enhance their effects. A major
benefit of using this method and also for the rising popularity is that immunotherapy promises to be less
toxic in nature than radiation, chemotherapy, and surgery. Additionally, in most cases, immunotherapy is
capable of offering a different mode of attack on the tumor. This allows both the patients and doctors to be
more confident of the results of the treatment with minimal side effects.
Cancer Immunotherapy Market & Clinical Pipeline Insight Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses
Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline
There are several advantages which are offered by immunotherapy in the treatment of some types of
cancers as compared to traditional chemotherapies and molecularly targeted agents. Generally, the
targeted therapies tend to depend mostly on the oncogenic dependency of the cell on specific pathways.
However, it is possible that in some cases, these cells could activate compensatory signaling to make them
resistant to these therapies. Thus, studies are being conducted to combine multiple receptor tyrosine kinase
inhibitors to prevent this emergence of resistance. However, with the use of such combinations, there is a
high risk of rising toxicities also, which could possibly limit their feasibility. On the contrary, immunotherapy
has the capability to target and eradicate micrometastatic disease which is dependent mainly on the protein
expression of the tumor cells. Thus, it becomes challenging for the individual cells to overcome a potent
immune response. Additionally, the extra toxicity which is associated with combinations of multiple tyrosine
kinase inhibitors is eradicated completely. Also, additional epitopes could be easily included in cancer
vaccines so as to reduce the chance of immune evasion.
For Report Contact: avinash@kuickresearch.com